Cargando…

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report

In the CodeBreaK 100 phase 2 study, sotorasib was active for patients with metastatic non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene homologue (KRAS) p.G12C mutation. However, patients with untreated and/or active brain metastases were excluded from the trial, and th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inno, Alessandro, Marchetti, Fabiana, Valerio, Matteo, Giaj Levra, Niccolò, Alongi, Filippo, Foti, Giovanni, Gori, Stefania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AboutScience 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318585/ https://www.ncbi.nlm.nih.gov/pubmed/37408855 http://dx.doi.org/10.33393/dti.2023.2593

Ejemplares similares

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?
por: Nicosia, Luca, et al.
Publicado: (2020)

Stereotactic radiosurgery for the treatment of brainstem metastases: a multicenter retrospective study
por: Nicosia, Luca, et al.
Publicado: (2022)

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
por: Inno, Alessandro, et al.
Publicado: (2023)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system
por: Giaj-Levra, Niccolò, et al.
Publicado: (2019)

Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis
por: Gobbini, Elisa, et al.
Publicado: (2021)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report
por: Li, Ce, et al.
Publicado: (2022)

Reduction of inter-observer differences in the delineation of the target in spinal metastases SBRT using an automatic contouring dedicated system
por: Giaj-Levra, Niccolò, et al.
Publicado: (2021)

Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
por: Koster, Kira-Lee, et al.
Publicado: (2022)

Intra-fraction and Inter-fraction analysis of a dedicated immobilization device for intracranial radiation treatment
por: Ong, Chin Loon, et al.
Publicado: (2020)

Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2022)

Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia
por: Molon, Giulio, et al.
Publicado: (2022)

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Remarkable Intracranial Response to Sotorasib in a Patient With KRAS(G12C)-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report
por: Yeh, Justin, et al.
Publicado: (2022)

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS(G12C)-Mutant Non–Small-Cell Lung Cancer
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment
por: Alongi, Filippo, et al.
Publicado: (2020)

Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
por: Zhang, Shannon S, et al.
Publicado: (2021)

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer
por: Chiou, Li-Wen, et al.
Publicado: (2023)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
por: Okada, Kohei, et al.
Publicado: (2023)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Hypofractionated Postoperative Radiotherapy in Prostate Cancer with Ialuril Soft Gels(®): Toxicity and Efficacy Analysis on a Retrospective Series of 305 Patients
por: Nicosia, Luca, et al.
Publicado: (2022)

1.5 T MR-Guided Daily Adapted SBRT on Lymph Node Oligometastases from Prostate Cancer
por: Nicosia, Luca, et al.
Publicado: (2022)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations
por: Lanman, Brian A., et al.
Publicado: (2022)

1.5T MR-Guided Daily Adaptive Stereotactic Body Radiotherapy for Prostate Re-Irradiation: A Preliminary Report of Toxicity and Clinical Outcomes
por: Cuccia, Francesco, et al.
Publicado: (2022)

PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer
por: Pastorello, Edoardo, et al.
Publicado: (2023)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
por: Iska, Sindu, et al.
Publicado: (2023)

ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial
por: Zilli, Thomas, et al.
Publicado: (2018)

Correction to: ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial
por: Zilli, Thomas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g5lsofr5bqf8tp35v74j34g0jt